• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dexcom Brings Mentorship to Centerfield, Welcomes New, Star Athletes to Its Ground-breaking NIL Program Dexcom U

    9/18/24 7:00:00 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care
    Get the next $DXCM alert in real time by email
    • Kicking off its third season, Dexcom U welcomes four new athletes, including Shelomi Sanders, a rising star on the Alabama A&M University basketball team, to its diverse roster of 20 athletes with diabetes representing 12 sports across 18 colleges
    • First-of-its-kind program continues to serve as a beacon of education and inspiration for the diabetes community through mentorship opportunities such as the Dexcom U Sports Camp which took place in June 2024

    DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today the launch of the third season of Dexcom U, the company's groundbreaking NIL (name, image, likeness) program exclusively for college athletes with diabetes.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240918060382/en/

    The Dexcom U 2024 roster consists of 20 athletes who all use Dexcom CGM to monitor their glucose levels and manage their diabetes (Graphic: Dexcom)

    The Dexcom U 2024 roster consists of 20 athletes who all use Dexcom CGM to monitor their glucose levels and manage their diabetes (Graphic: Dexcom)

    Heralded by Ad Age as a Top 5 NIL Partnership after its inaugural season in 2022, the 2024 Dexcom U season welcomes four new athletes from top schools including Alabama A&M, University of Southern California, University of Missouri and Florida Gulf Coast University. The roster includes 20 athletes across 12 different sports including beach volleyball, water polo, lacrosse, cheerleading and more.

    All Dexcom U athletes use Dexcom continuous glucose monitoring (CGM) technology to manage their diabetes. Dexcom CGMs consist of a small, wearable sensor that continually measures and sends glucose data wirelessly to a smart device* or receiver, giving users accurate1 real-time glucose data that empowers them to train and compete at a high level, breaking new barriers in their respective sports.

    "Heading into year three of this unique program, we want to amplify the impact Dexcom U athletes are making on the next generation of people with diabetes," said Teri Lawver, executive vice president and chief commercial officer at Dexcom. "After supporting nearly 30 college athletes since the program's inception in 2022, with multiple reaching professional ranks, our Dexcom U roster is proof that with the right support and technology, people with diabetes can achieve their athletic dreams."

    With research that reveals representation for people with diabetes can help inspire up-and-coming college and professional athletes2, Dexcom has doubled down on fuelling mentorships between aspiring young athletes and those playing at the collegiate or pro levels.

    To bring the program's mentorship pillar to life, Dexcom hosted the first-ever Dexcom U Sports Camp in San Diego during the offseason. The camp brought together professional athletes including Indianapolis Colts wide receiver Adonai Mitchell and Miami Dolphins long snapper Blake Ferguson, Dexcom U team members and young athletes ranging from ages 11 to 15 — all who have three things in common: a diabetes diagnosis, a passion for sports, and pride in wearing Dexcom CGM technology like Dexcom G7. At the camp, Dexcom U athletes were paired with mentees following a dynamic day of activities. Since then, they regularly check in on each other, offering support and reminders that diabetes doesn't have to hold them back.

    The Dexcom U 2024 roster consists of 20 athletes, with four new and 16 returning members, who all use Dexcom CGM to monitor their glucose levels and manage their diabetes:

    • Amber Jackson, Track & Field, University of Louisville
    • Ava DeStefon, Cheerleading, Clemson University
    • Ben Mirisch, Water Polo, University of Southern California
    • Bri Carrasquillo, Lacrosse, University of Oregon
    • Caleb Fauria, Football, University of Delaware
    • Dante Vasquez, Football, Springfield College
    • Isaac Traudt, Basketball, Creighton University
    • Jaci Carpenter, Beach Volleyball, Florida Gulf Coast University
    • Jaxon Dowell, Golf, University of Oklahoma
    • Jessica Walter, Softball, Providence College
    • Joshua Meriwether, Football, Tennessee State University
    • Leo Giannoni, Baseball, Florida Gulf Coast University
    • Madison Moraja, Track & Field, North Carolina State University
    • Marlee Fray, Soccer, Oral Roberts University
    • Nicholas Hahne, Cheerleading, University of Notre Dame
    • Paris Husic, Track & Field, Clemson University
    • Raegan Lantz, Volleyball, Miami (OH) University
    • Sam Horn, Football & Baseball, University of Missouri
    • Shelomi Sanders, Basketball, Alabama A&M
    • Tristan Wakefield, Rowing, Syracuse University

    "I joined Dexcom U because it's important to me to share my story to be a voice for others and show I won't be deterred from achieving my goals despite living with diabetes," said Shelomi Sanders, first-year member of Dexcom U and basketball player at Alabama A&M. "Not only does my Dexcom G7 give me and my loved ones peace of mind, but the connectivity features I'm able to tap into through my automated insulin delivery system help me elevate my game to the next level."

    Dexcom will continue to offer free educational resources to help other athletes with diabetes better understand how to manage their condition. These resources also help parents, coaches and teammates better understand the disease and learn how to support those with diabetes. These resources consist of first-hand advice from Dexcom U athletes as well as tips for the next generation of athletes with diabetes so they can better manage their condition, stay active and feel their best physically and mentally – on and off the field.

    "Being part of such a special program like Dexcom U means the world to me, and it's empowering to know there's a community out there that understands the additional hurdles that athletes with diabetes have to overcome," said Joshua Meriwether, second-year member of the program and football player at Tennessee State University. "As a young teenager I dreamed of having a support system like I do with my Dexcom U teammates, so being able to mentor and inspire the next generation of athletes with diabetes is extremely rewarding."

    To learn more about Dexcom U and access the educational resources, visit https://www.dexcom.com/dexcomu.

    About Dexcom, Inc.

    DexCom, Inc. empowers people to take control of health through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, Calif., and with operations across Europe and select parts of Asia/Oceania, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers and providers, Dexcom works to simplify and improve diabetes management around the world. For more information on Dexcom, visit https://www.dexcom.com/about.

    *Smart device sold separately. For a list of compatible devices, visit www.Dexcom.com/compatibility.

    1 Welsh JB, et al. J Diabetes Sci Technol. 2024;18(1):143-7.

    2 Dexcom, U.S. data on file, September 2022

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240918060382/en/

    Get the next $DXCM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DXCM

    DatePrice TargetRatingAnalyst
    1/12/2026$71.00Equal Weight → Underweight
    Barclays
    12/2/2025$75.00Equal-Weight → Overweight
    Morgan Stanley
    11/25/2025$68.00In-line
    Evercore ISI
    10/21/2025$85.00Buy
    Stifel
    9/8/2025Outperform → Perform
    Oppenheimer
    8/21/2025$100.00Buy
    Argus
    6/16/2025$102.00Buy
    Truist
    5/30/2025$104.00Buy
    Goldman
    More analyst ratings

    $DXCM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Dexcom Announces Upcoming Conference Presentation

    DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the 47th Annual Raymond James Institutional Investors Conference on Monday, March 2, 2026. The live presentation is scheduled to begin at approximately 1:05 PM EST and will be concurrently webcast. Links to the webcast will be available on the Dexcom Investor Relations website at investors.dexcom.com and will be archived there for future reference. About DexCom, Inc. Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transf

    2/25/26 8:30:00 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Dexcom Reports Fourth Quarter and Fiscal Year 2025 Financial Results

    DexCom, Inc. (NASDAQ:DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights: Revenue grew 13% year-over-year to $1.260 billion on a reported basis and 12% year-over-year on an organic1 basis. U.S. revenue grew 11% and international revenue grew 18% on a reported basis and 15% on an organic1 basis, all on a year-over-year basis. GAAP operating income of $323.0 million or 25.6% of revenue, an increase of 860 basis points compared to the fourth quarter of 2024. Non-GAAP operating income* of $331.5 million or 26.3% of reported revenue, an increase of 750 basis points compared to the fourth

    2/12/26 4:03:00 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Stelo Adds Enhanced Smart Meal Logging Features as Dexcom Continues to Transform Personal Glucose Management

    Enhanced Smart Food Logging experience now provides nutritional breakdown of meals Advanced AI-enabled features will deliver easy meal tracking to transform daily metabolic health management Redesigned and personalized Daily Insights will reveal how daily performance and behaviors impact health Dexcom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced it will roll out an advanced AI-enabled enhancement to Stelo that will transform how users understand their glucose health and take steps in achieving their long-term health goals. The newest features will launch nationwide in the coming weeks. This press release features multimedia. View the full release here:

    2/4/26 8:30:00 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    SEC Filings

    View All

    SEC Form 10-K filed by DexCom Inc.

    10-K - DEXCOM INC (0001093557) (Filer)

    2/12/26 5:20:56 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    DexCom Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - DEXCOM INC (0001093557) (Filer)

    2/12/26 4:03:42 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    DexCom Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - DEXCOM INC (0001093557) (Filer)

    1/12/26 7:30:45 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Heller Bridgette P sold $68,826 worth of shares (1,012 units at $68.01), decreasing direct ownership by 4% to 26,019 units (SEC Form 4)

    4 - DEXCOM INC (0001093557) (Issuer)

    2/17/26 4:36:44 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    President, CEO, and Director Leach Jacob Steven was granted 8,310 shares and covered exercise/tax liability with 3,058 shares, increasing direct ownership by 2% to 337,051 units (SEC Form 4)

    4 - DEXCOM INC (0001093557) (Issuer)

    2/2/26 4:46:44 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    EVP, Chief HR Officer Stern Sadie was granted 7,123 shares and covered exercise/tax liability with 2,656 shares, increasing direct ownership by 4% to 109,690 units (SEC Form 4)

    4 - DEXCOM INC (0001093557) (Issuer)

    2/2/26 4:46:39 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Dexcom downgraded by Barclays with a new price target

    Barclays downgraded Dexcom from Equal Weight to Underweight and set a new price target of $71.00

    1/12/26 8:59:23 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Dexcom upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Dexcom from Equal-Weight to Overweight and set a new price target of $75.00

    12/2/25 8:17:55 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Evercore ISI initiated coverage on Dexcom with a new price target

    Evercore ISI initiated coverage of Dexcom with a rating of In-line and set a new price target of $68.00

    11/25/25 8:40:45 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & COO Leach Jacob Steven bought $1,001,702 worth of shares (18,200 units at $55.04), increasing direct ownership by 6% to 331,697 units (SEC Form 4)

    4 - DEXCOM INC (0001093557) (Issuer)

    11/10/25 7:13:08 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    Leadership Updates

    Live Leadership Updates

    View All

    Dexcom Appoints Euan Ashley to Board of Directors

    DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Euan Ashley to its Board of Directors, effective October 24, 2025. Dr. Ashley is a renowned researcher, entrepreneur, and clinician with extensive leadership experience at healthcare research institutions and private organizations. He currently serves as Chair of the Department of Medicine at Stanford University, overseeing Stanford's largest department with 15 divisions and over 800 faculty. Dr. Ashley's research extends across precision medicine, data science, artificial intelligence, and digital health. He has also co-founded seven biotechnology companies and serves as the co-directo

    10/27/25 4:15:00 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Synchron Expands Executive Team with Appointment of Andy Rasdal as Chief of Staff and Mark Brister as VP R&D

    Medical device leaders who have built and scaled category-defining products join Synchron to help drive its next-generation brain-computer interface platform as well as accelerate towards commercialization Synchron, a category-defining brain-computer interface (BCI) company, today announced the appointment of Andy Rasdal as Chief of Staff and Mark Brister as VP R&D. The appointments bring deep experience in launching and scaling category-leading medical devices, positioning Synchron to advance its Stentrode® BCI through U.S. clinical trials and prepare for global market entry. Mr. Rasdal, who joined Synchron's Board of Directors in 2023, will transition into a full-time executive role

    8/19/25 8:00:00 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Dexcom Unveils Season 4 Roster for Game-Changing NIL Program at Signing Day Camp Hosted by Mark Andrews

    Dexcom's first-of-its-kind NIL program welcomes 13 new athletes and eight returning team members, including San Diego State University basketball standout Miles Byrd and Alabama A&M University's Shelomi Sanders The trailblazing program empowers college athletes with Type 1 diabetes to break barriers in sports and inspire their communities, as showcased at the Dexcom U Signing Day Camp, a new addition to the program, earlier this month DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the launch of the fourth season of Dexcom U, the company's one-of-a-kind NIL (Name, Image and Likeness) program exclusively for college athletes with diabetes. This pr

    7/17/25 8:30:00 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    Financials

    Live finance-specific insights

    View All

    Dexcom Reports Fourth Quarter and Fiscal Year 2025 Financial Results

    DexCom, Inc. (NASDAQ:DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights: Revenue grew 13% year-over-year to $1.260 billion on a reported basis and 12% year-over-year on an organic1 basis. U.S. revenue grew 11% and international revenue grew 18% on a reported basis and 15% on an organic1 basis, all on a year-over-year basis. GAAP operating income of $323.0 million or 25.6% of revenue, an increase of 860 basis points compared to the fourth quarter of 2024. Non-GAAP operating income* of $331.5 million or 26.3% of reported revenue, an increase of 750 basis points compared to the fourth

    2/12/26 4:03:00 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Dexcom Schedules Fourth Quarter and Fiscal Year 2025 Earnings Release and Conference Call for February 12, 2026 at 4:30 p.m. Eastern Time.

    DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its fourth quarter and fiscal year 2025 financial results after market close on Thursday, February 12, 2026. Management will hold a conference call to review the company's fourth quarter and fiscal year 2025 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will be archived there for future reference. To listen to the conference call, please dial (888) 414-4585 (US/Canada) or (646) 960-0331 (International) and use the confirmation ID "9430114" appr

    1/27/26 8:30:00 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Dexcom Reports Preliminary, Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook

    DexCom, Inc. (NASDAQ:DXCM) today reported preliminary, unaudited results for the fourth quarter ended December 31, 2025 with total revenue of approximately $1.260 billion, an increase of 13% over the fourth quarter of 2024. U.S. revenue is expected to be approximately $892 million, representing growth of 11% over the fourth quarter of 2024. International revenue is expected to be approximately $368 million, an increase of 18% over the fourth quarter of 2024. For fiscal 2025, total preliminary, unaudited revenue is approximately $4.662 billion, an increase of 16% over 2024. In conjunction with the preliminary fourth quarter results, the company is also reiterating 2025 non-GAAP gross profi

    1/12/26 7:30:00 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by DexCom Inc. (Amendment)

    SC 13G/A - DEXCOM INC (0001093557) (Subject)

    2/13/24 5:02:33 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by DexCom Inc. (Amendment)

    SC 13G/A - DEXCOM INC (0001093557) (Subject)

    2/9/23 11:16:37 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by DexCom Inc. (Amendment)

    SC 13G/A - DEXCOM INC (0001093557) (Subject)

    2/9/22 3:43:37 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care